https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%8F%8C%E9%87%8D%E6%89%93%E5%87%BB%E6%B7%8B%E5%B7%B4%E7%98%A4
双重打击淋巴瘤 - 版本历史
2026-05-06T12:34:57Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E5%8F%8C%E9%87%8D%E6%89%93%E5%87%BB%E6%B7%8B%E5%B7%B4%E7%98%A4&diff=316106&oldid=prev
2026年1月28日 (三) 19:59 77921020
2026-01-28T19:59:29Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月28日 (三) 19:59的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l3" >第3行：</td>
<td colspan="2" class="diff-lineno">第3行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <strong>双重打击淋巴瘤</strong>（Double-Hit Lymphoma, <strong>DHL</strong>）在最新 WHO 分类中被称为“伴有 <i>MYC</i> 和 <i>BCL2</i> 和/或 <i>BCL6</i> 重排的高级别 B 细胞淋巴瘤”（HGBL-DH/TH）。这是一种预后极差的侵袭性恶性肿瘤，其分子特征是同时发生 <strong><del class="diffchange diffchange-inline">$</del>MYC<del class="diffchange diffchange-inline">$</del></strong> 癌基因（位于 8q24）易位与 <strong><del class="diffchange diffchange-inline">$</del>BCL2<del class="diffchange diffchange-inline">$</del></strong>（位于 18q21）或 <strong><del class="diffchange diffchange-inline">$</del>BCL6<del class="diffchange diffchange-inline">$</del></strong>（位于 3q27）基因的易位。由于同时具备了细胞增殖失控（MYC 驱动）和细胞凋亡受阻（BCL2 驱动）的双重生存优势，DHL 对标准免疫化疗（如 R-CHOP）反应不佳，通常需要更高强度的治疗方案。</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <strong>双重打击淋巴瘤</strong>（Double-Hit Lymphoma, <strong>DHL</strong>）在最新 WHO 分类中被称为“伴有 <i>MYC</i> 和 <i>BCL2</i> 和/或 <i>BCL6</i> 重排的高级别 B 细胞淋巴瘤”（HGBL-DH/TH）。这是一种预后极差的侵袭性恶性肿瘤，其分子特征是同时发生 <strong><ins class="diffchange diffchange-inline"><i></ins>MYC<ins class="diffchange diffchange-inline"></i></ins></strong> 癌基因（位于 8q24）易位与 <strong><ins class="diffchange diffchange-inline"><i></ins>BCL2<ins class="diffchange diffchange-inline"></i></ins></strong>（位于 18q21）或 <strong><ins class="diffchange diffchange-inline"><i></ins>BCL6<ins class="diffchange diffchange-inline"></i></ins></strong>（位于 3q27）基因的易位。由于同时具备了细胞增殖失控（MYC 驱动）和细胞凋亡受阻（BCL2 驱动）的双重生存优势，DHL 对标准免疫化疗（如 R-CHOP）反应不佳，通常需要更高强度的治疗方案。</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l30" >第30行：</td>
<td colspan="2" class="diff-lineno">第30行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">核心基因</th></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">核心基因</th></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><del class="diffchange diffchange-inline">$</del>MYC<del class="diffchange diffchange-inline">$ </del>+ <del class="diffchange diffchange-inline">$</del>BCL2<del class="diffchange diffchange-inline">$ </del>/ <del class="diffchange diffchange-inline">$</del>BCL6<del class="diffchange diffchange-inline">$</del></td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><ins class="diffchange diffchange-inline"><i></ins>MYC<ins class="diffchange diffchange-inline"></i> </ins>+ <ins class="diffchange diffchange-inline"><i></ins>BCL2<ins class="diffchange diffchange-inline"><</ins>/<ins class="diffchange diffchange-inline">i> / <i></ins>BCL6<ins class="diffchange diffchange-inline"></i></ins></td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l56" >第56行：</td>
<td colspan="2" class="diff-lineno">第56行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <ul style="padding-left: 25px; color: #334155;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <ul style="padding-left: 25px; color: #334155;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>MYC (油门卡死)：</strong> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>MYC (油门卡死)：</strong> </div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <br><i>MYC</i> 基因易位（常与 IgH 基因融合）导致 c-Myc 蛋白过表达，驱动细胞无限制地进入细胞周期，促进细胞极速增殖和代谢重编程（Warburg 效应）。</li></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <br><i>MYC</i> 基因易位（常与 <ins class="diffchange diffchange-inline"><i></ins>IgH<ins class="diffchange diffchange-inline"></i> </ins>基因融合）导致 c-Myc 蛋白过表达，驱动细胞无限制地进入细胞周期，促进细胞极速增殖和代谢重编程（Warburg 效应）。</li></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>BCL2 (刹车失灵)：</strong> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>BCL2 (刹车失灵)：</strong> </div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <br><i>BCL2</i> <del class="diffchange diffchange-inline">基因易位（$t</del>(14;18)<del class="diffchange diffchange-inline">$</del>）导致 Bcl-2 蛋白高表达。Bcl-2 是强效的抗凋亡蛋白，能阻断线粒体凋亡途径。正常情况下，<i>MYC</i> 的异常激活会诱导细胞凋亡，但 <i>BCL2</i> 的存在使得这些本该死亡的癌细胞得以存活。</li></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <br><i>BCL2</i> <ins class="diffchange diffchange-inline">基因易位（t</ins>(14;18)）导致 Bcl-2 蛋白高表达。Bcl-2 是强效的抗凋亡蛋白，能阻断线粒体凋亡途径。正常情况下，<i>MYC</i> 的异常激活会诱导细胞凋亡，但 <i>BCL2</i> 的存在使得这些本该死亡的癌细胞得以存活。</li></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>协同致死性：</strong> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <li style="margin-bottom: 12px;"><strong>协同致死性：</strong> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <br>二者结合导致肿瘤不仅长得快（高 Ki-67 指数），而且杀不死（化疗耐药），临床进展极快。</li></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <br>二者结合导致肿瘤不仅长得快（高 Ki-67 指数），而且杀不死（化疗耐药），临床进展极快。</li></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l90" >第90行：</td>
<td colspan="2" class="diff-lineno">第90行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">预后 (R-CHOP)</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">预后 (R-CHOP)</td></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>极差</strong> (5年 OS <del class="diffchange diffchange-inline">< </del>30%)</td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>极差</strong> (5年 OS <ins class="diffchange diffchange-inline">&lt; </ins>30%)</td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">中等/较差</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px; border: 1px solid #cbd5e1;">中等/较差</td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td></tr>
<!-- diff cache key yixue20260209:diff::1.12:old-316105:rev-316106 -->
</table>
77921020
https://www.yiliao.com/index.php?title=%E5%8F%8C%E9%87%8D%E6%89%93%E5%87%BB%E6%B7%8B%E5%B7%B4%E7%98%A4&diff=316105&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-28T19:57:05Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>双重打击淋巴瘤</strong>（Double-Hit Lymphoma, <strong>DHL</strong>）在最新 WHO 分类中被称为“伴有 <i>MYC</i> 和 <i>BCL2</i> 和/或 <i>BCL6</i> 重排的高级别 B 细胞淋巴瘤”（HGBL-DH/TH）。这是一种预后极差的侵袭性恶性肿瘤，其分子特征是同时发生 <strong>$MYC$</strong> 癌基因（位于 8q24）易位与 <strong>$BCL2$</strong>（位于 18q21）或 <strong>$BCL6$</strong>（位于 3q27）基因的易位。由于同时具备了细胞增殖失控（MYC 驱动）和细胞凋亡受阻（BCL2 驱动）的双重生存优势，DHL 对标准免疫化疗（如 R-CHOP）反应不佳，通常需要更高强度的治疗方案。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">双重打击淋巴瘤</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">High-Grade B-Cell Lymphoma (DHL) (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">金标准：FISH 检测到的双易位</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">疾病特征</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">WHO 分类</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">HGBL w/ rearrangements</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">核心基因</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">$MYC$ + $BCL2$ / $BCL6$</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">确诊方法</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>FISH</strong> (荧光原位杂交)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">细胞来源</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">生发中心 B 细胞 (GCB)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">侵袭性</th><br />
<td style="padding: 6px 12px; color: #b91c1c;"><strong>极高</strong> (Highly Aggressive)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子病理：生与死的失控</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
DHL 的极度恶性源于两个关键致癌通路的协同效应，被称为<strong>“油门与刹车同时失灵”</strong>：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>MYC (油门卡死)：</strong> <br />
<br><i>MYC</i> 基因易位（常与 IgH 基因融合）导致 c-Myc 蛋白过表达，驱动细胞无限制地进入细胞周期，促进细胞极速增殖和代谢重编程（Warburg 效应）。</li><br />
<li style="margin-bottom: 12px;"><strong>BCL2 (刹车失灵)：</strong> <br />
<br><i>BCL2</i> 基因易位（$t(14;18)$）导致 Bcl-2 蛋白高表达。Bcl-2 是强效的抗凋亡蛋白，能阻断线粒体凋亡途径。正常情况下，<i>MYC</i> 的异常激活会诱导细胞凋亡，但 <i>BCL2</i> 的存在使得这些本该死亡的癌细胞得以存活。</li><br />
<li style="margin-bottom: 12px;"><strong>协同致死性：</strong> <br />
<br>二者结合导致肿瘤不仅长得快（高 Ki-67 指数），而且杀不死（化疗耐药），临床进展极快。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊断与鉴别：DHL vs DEL</h2><br />
<br />
<div style="background-color: #fff7ed; border-left: 5px solid #ea580c; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<p style="margin: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
<strong>警惕混淆：</strong> 临床上需严格区分 <strong>双重打击淋巴瘤 (DHL)</strong> 与 <strong>双表达淋巴瘤 (DEL)</strong>。DHL 基于<strong>基因重排 (FISH)</strong>，预后极差；而 DEL 基于<strong>蛋白表达 (IHC)</strong>，预后介于 DHL 和普通 DLBCL 之间。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">特征</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #b91c1c; width: 40%;">双重打击 (DHL/HGBL-DH)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">双表达 (DEL)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">定义基础</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>遗传学 (FISH)</strong><br>检测到基因断裂/融合</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>免疫组化 (IHC)</strong><br>检测到蛋白过表达</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">发生率</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">约占 DLBCL 的 5-10%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">约占 DLBCL 的 30%</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">预后 (R-CHOP)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>极差</strong> (5年 OS < 30%)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">中等/较差</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：超越 R-CHOP</h2><br />
<br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #1e40af; font-size: 1.1em;">强化诱导治疗</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
由于 DHL 对标准 R-CHOP 方案耐药，NCCN 指南推荐使用更高强度的免疫化疗方案：<br />
<br>1. <strong>DA-EPOCH-R：</strong> 剂量调整的依托泊苷、泼尼松、长春新碱、环磷酰胺、多柔比星 + 利妥昔单抗。是目前最常用的首选方案。<br />
<br>2. <strong>R-HyperCVAD：</strong> 包含甲氨蝶呤和阿糖胞苷的交替方案。<br />
<br>3. <strong>CNS 预防：</strong> DHL 患者中枢神经系统复发风险高，必须进行鞘内注射或全身性甲氨蝶呤预防。<br />
<br>4. <strong>新疗法：</strong> 复发/难治性患者可考虑 CD19 CAR-T (如 Axi-cel) 或双特异性抗体。<br />
</p><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Swerdlow SH, et al. (2016).</strong> <em>The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</em> <strong>[[Blood]]</strong>. <br><br />
<span style="color: #475569;">[点评]：WHO 权威分类，正式确立了 HGBL (伴 MYC 和 BCL2/BCL6 重排) 作为一个独立的疾病实体。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Dunleavy K, et al. (2018).</strong> <em>Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.</em> <strong>[[The Lancet Haematology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：确立了 DA-EPOCH-R 在 MYC 重排及双重打击淋巴瘤治疗中的核心地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>Rosenthal A, et al. (2017).</strong> <em>Double-Hit Lymphoma: Clinicopathologic Features, Management, and Outcome.</em> <strong>[[Journal of Clinical Oncology]]</strong>. <br><br />
<span style="color: #475569;">[点评]：全面综述了 DHL 的临床病理特征及不同治疗方案的预后对比。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
双重打击淋巴瘤 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">相关疾病</td><br />
<td style="padding: 10px 15px; color: #334155;">[[弥漫大B细胞淋巴瘤]] (DLBCL) • [[伯基特淋巴瘤]] (Burkitt) • [[三重打击淋巴瘤]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">分子检测</td><br />
<td style="padding: 10px 15px; color: #334155;">[[FISH]] (断裂分离探针) • [[Ki-67]] (增殖指数) • [[IHC]] (C-Myc/Bcl-2)</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">前沿疗法</td><br />
<td style="padding: 10px 15px; color: #334155;">[[CAR-T细胞治疗]] • [[双特异性抗体]] (Glofitamab) • [[Bcl-2抑制剂]] (Venetoclax)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020